{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:34:47Z","timestamp":1791178487049,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ctrv.2011.07.004","type":"journal-article","created":{"date-parts":[[2011,8,15]],"date-time":"2011-08-15T08:07:24Z","timestamp":1313395644000},"page":"241-248","source":"Crossref","is-referenced-by-count":25,"title":["Physician\u2019s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML"],"prefix":"10.1016","volume":"38","author":[{"given":"Gianantonio","family":"Rosti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ctrv.2011.07.004_b0005","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.ctrv.2011.07.004_b0010","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2011.07.004_b0015","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ctrv.2011.07.004_b0020","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2011.07.004_b0025","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.07.004_b0030","unstructured":"Tasigna (nilotinib) Prescribing Information; 2011. Available from: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf."},{"issue":"4","key":"10.1016\/j.ctrv.2011.07.004_b0035","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance. 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2011.07.004_b0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood.V114.22.2205.2205","article-title":"Nilotinib 800 mg daily as frontline therapy of Ph + chronic myeloid leukemia: dose delivered and safety profile for the GIMEMA CML Working Party","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ctrv.2011.07.004_b0045","first-page":"487","article-title":"Comparison of nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year","volume":"28","author":"Larson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2011.07.004_b0050","first-page":"1272","article-title":"Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study","volume":"114","author":"le Coutre","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2011.07.004_b0055","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2011.07.004_b0060","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE) v 4. 2010."},{"key":"10.1016\/j.ctrv.2011.07.004_b0065","unstructured":"Tasigna (nilotinib) [package insert]. Stein, Switzerland: Novartis Pharma Stein AG; 2010."},{"issue":"12","key":"10.1016\/j.ctrv.2011.07.004_b0070","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2011.07.004_b0075","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.leu.2402917","article-title":"Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR","volume":"17","author":"Hui","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2011.07.004_b0080","first-page":"227","article-title":"Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"88","author":"Marin","year":"2003","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.ctrv.2011.07.004_b0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood.V114.22.142.142","volume":"114","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2011.07.004_b0090","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.V114.22.866.866","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2011.07.004_b0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ctrv.2011.07.004_b0100","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.leu.2402868","article-title":"Intramuscular edema as a complication of treatment with imatinib","volume":"17","author":"Shimazaki","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2011.07.004_b0105","first-page":"2929","article-title":"Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors","volume":"61","author":"Pietras","year":"2001","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2011.07.004_b0110","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2011.07.004_b0115","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/0091270009346061","article-title":"Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib","volume":"50","author":"Yin","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ctrv.2011.07.004_b0120","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2011.07.004_b0125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2011.07.004_b0130","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2011.07.004_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2011.07.004_b0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nm0107-15a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Rosti","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2011.07.004_b0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13b","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Gambacorti-Passerini","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2011.07.004_b0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0107-14","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Atallah","year":"2007","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.ctrv.2011.07.004_b0155","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2011.07.004_b0160","article-title":"In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: dasatinib, imatinib and nilotinib","volume":"111","author":"Freebern","year":"2007","journal-title":"Blood"},{"issue":"18S","key":"10.1016\/j.ctrv.2011.07.004_b0165","article-title":"Rare incidence of congestive heart failure (CHF) in gastrointestinal stromal tumor (GIST) and other sarcoma patients (pts) receiving imatinib mesylate (IM) therapy","volume":"25","author":"Khakoo","year":"2007","journal-title":"J Clinic Oncol ASCO Ann Meet Proc"},{"key":"10.1016\/j.ctrv.2011.07.004_b0170","unstructured":"Sprycel (dasatinib) [package insert]. Princeton, NJ: Bristol Meyers Squibb Company; 2010."},{"issue":"9604","key":"10.1016\/j.ctrv.2011.07.004_b0175","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2011.07.004_b0180","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2011.07.004_b0185","first-page":"457","article-title":"Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the ENACT (expanding nilotinib access in clinical trials) study","volume":"114","author":"Le Coutre","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2011.07.004_b0190","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ctrv.2011.07.004_b0195","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2011.07.004_b0200","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2009.010496","article-title":"Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure","volume":"94","author":"Palandri","year":"2009","journal-title":"Haematologica"},{"issue":"s2","key":"10.1016\/j.ctrv.2011.07.004_b0205","first-page":"255","article-title":"Final safety analysis of 1, 793 CML patients from ENACT (expanding nilotinib access in clinical trials) study in adult patients with imatinib-resistant or \u2013 intolerant chronic myeloid leukemia (CML)","volume":"94","author":"Nicolini","year":"2009","journal-title":"Haematologica"},{"issue":"s2","key":"10.1016\/j.ctrv.2011.07.004_b0210","first-page":"55","article-title":"Active dose re-escalation of nilotinib following dose reduction is associated with improved efficacy in patients with chronic phase chronic myeloid leukemia (CML-CP) who fail imatinib","volume":"95","author":"Nicolini","year":"2010","journal-title":"Haematologica"},{"issue":"s2","key":"10.1016\/j.ctrv.2011.07.004_b0215","first-page":"257","article-title":"Expanding nilotinib access in clinical trials (ENACT) study in adult patients (pts) with imatinib-resistant or \u2013 intolerant chronic myeloid leukemia (CML): subgroup analysis of patients who failed prior dasatinib therapy","volume":"94","author":"Nicolini","year":"2009","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.ctrv.2011.07.004_b0220","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood.V114.22.3295.3295","article-title":"Nilotinib responses and tolerability confirmed in North American patients with chronic myeloid leukemia (CML) from ENACT (Expanding Nilotinib Access in Clinical Trials)","volume":"114","author":"Powell","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2011.07.004_b0225","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V114.22.2201.2201","article-title":"Molecular response, efficacy and safety analysis of 168 adult French patients with chronic myeloid leukemia (CML) in chronic phase (CP) from the ENACT (expanding nilotinib access in clinical trials) study","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737211001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737211001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T08:24:08Z","timestamp":1592814248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737211001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0305737211001599"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2011.07.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}